Table 1.
Genomic alterations of HER family members in gastric cancer cell lines
| Cell line | Sex | HER family status | Afatinib | Neratinib | Gefitinib | Pertuzumab | Trastuzumab | ||
|---|---|---|---|---|---|---|---|---|---|
| IC50 (nmol/L) | Sensitivity | IC50 (nmol/L) | Sensitivity | IC50 (nmol/L) | IC50 (μg/mL) | IC50 (μg/mL) | |||
| NUGC4 | F |
HER2 amp (CNV, 6.95) EGFR amp |
0.7 | High | 0.8 | High | 168.2 | >103 | >103 |
| NCI‐N87 | M | HER2 amp (CNV, 62.41) | 3.1 | High | <0.16 | High | 1110.3 | >103 | >103 |
| NUGC3 | M | HER3 mut (G1273R) | 21.3 | High | 30.7 | High | 447.2 | >103 | >103 |
| SNU‐216 | F | HER2 amp (CNV, 13.40) | 29.0 | High | 47.7 | High | 6391.9 | >103 | >103 |
| GCIY | F | HER2 amp (CNV, 7.28) | 39.5 | High | 63.8 | High | 449.4 | >103 | >103 |
| MKN7 | M | HER2 amp (CNV, 16.30) | 798.4 | Moderate | 757.3 | Moderate | >104 | >103 | >103 |
| KATO‐III | M | N/A | 1398.6 | Insensitive | 320.1 | Moderate | 7640.9 | >103 | >103 |
| SNU‐16 | F | N/A | 1754.2 | Insensitive | 1055.7 | Insensitive | >104 | >103 | >103 |
| SH‐10‐TC | N/A | N/A | 2524.1 | Insensitive | 3417.1 | Insensitive | >104 | >103 | >103 |
| ECC10 | M | HER2 mut (L755S) | 4461.7 | Insensitive | 519.2 | Moderate | >104 | >103 | >103 |
| MKN74 | M | N/A | 6758.1 | Insensitive | >104 | Insensitive | >104 | >103 | >103 |
| OCUM‐1 | F | N/A | >104 | Insensitive | 5000 | Insensitive | >104 | >103 | >103 |